
Opinion|Videos|March 13, 2025
How BTK Inhibitors Might Address Unmet Treatment Needs in CSU
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors appear to offer faster symptom relief and higher complete response rates compared with current chronic spontaneous urticaria (CSU) treatments like antihistamines and omalizumab while potentially requiring less frequent dosing and showing favorable safety profiles.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do data from these trials compare to results you see in practice with other, non-BTK options for CSU management?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
2
Prevalence and Recognition of Hypercortisolism
3
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
4
METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy
5


























































































